Impact of 18F-fluoride PET on intended management of patients with cancers other than prostate cancer: Results from the National Oncologic PET Registry

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1054-1061

  Hillner, Bruce E ^a   Siegel, Barry A ^b   Hanna, Lucy ^c   Duan, Fenghai ^c   Shields, Anthony F ^d   Quinn, Bruce ^e   Coleman, R Edward ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Foley Hoag LLC   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone scintigraphy; Breast cancer; Lung cancer; Patient registry; Positron emission tomography; Prostate cancer; Sodium fluoride diagnostic use

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; SODIUM FLUORIDE F 18; FLUORINE; SODIUM FLUORIDE;

ARTICLE; BLADDER CANCER; BONE CANCER; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER THERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MYELOMA; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BIOPSY; WATCHFUL WAITING; COHORT ANALYSIS; DIAGNOSTIC USE; FEMALE; MALE; NEOPLASMS; PATIENT CARE; REGISTER; SCINTISCANNING; STATISTICS AND NUMERICAL DATA;

COHORT STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; NEOPLASMS; PATIENT CARE MANAGEMENT; POSITRON-EMISSION TOMOGRAPHY; REGISTRIES; SODIUM FLUORIDE;

EID: 84904101061     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.135475     Document Type: Article

References (30)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593. (Pubitemid 37328925)
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
3. Coleman RE. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2012;9:76-78.
4. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221-1227.
5. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2013;11(suppl 3):S-1-S-50.
6. 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
7. Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009;10:606-614.
8. Nielsen OS, Munro A, Tannock I. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
9. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
10. 18F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50:128-139.
11. 99mTc-MDP bone scan. Jpn J Radiol. 2013;31:262-269.
12. 18F-fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730-1736.
13. 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med. 2013;38:616-621.
14. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804.
15. 18F PET. J Nucl Med. 1999;40:1623-1629. (Pubitemid 29471151)
16. Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31:637-645.
17. 18F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252-259.
18. Positron Emission Tomography. (NaF-18) to Identify Bone Metastasis of Cancer. Pub 100-03 Medicare National Coverage Determinations - Transmittal 119. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/ 2010-Transmittals-Items/CMS1234261.html. Accessed April 22, 2014.
19. 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574-581.
20. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med. 2007;48:1901-1908. (Pubitemid 350099337)
21. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155-2161.
22. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med. 2008;49:1928-1935.
23. Hillner BE, Siegel BA, Shields AF, et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer. 2009;115:410-418.
24. 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. J Nucl Med. 2012;53:831-837.
25. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013;11:1471-1479.
26. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5S):e211S-250S.
27. Theriault RL, Carlson RW, Allred C, et al. Breast cancer, version 3.2013. J Natl Compr Canc Netw. 2013;11:753-760.
28. Hillner BE, Tosteson AN, Tosteson TD, et al. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry. J Nucl Med. 2013;54:2024-2031.
29. Hillner BE, Tosteson TD, Tosteson AN, et al. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry. Med Care. 2013;51:361-367.
30. F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets. NCT00882609. http://clinicaltrials.gov/show/NCT00882609. Accessed April 22, 2014.